Zurich, Switzerland, August 18, 2009 / b3c newswire /
-Neurimmune Therapeutics AG today announced that, following the successful completion of key research milestones, its lead human therapeutic antibody for Alzheimers disease has advanced into preclinical development, triggering milestone payments of an undisclosed amount from Biogen Idec (NASDAQ: BIIB). Neurimmune partnered with Biogen Idec for the worldwide development and commercialization of novel, fully human antibodies for the treatment of Alzheimers disease in November 2007. The alliance focuses on the development of antibodies that bind to amyloid beta (Abeta), a pathogenic molecule thought to cause neurodegeneration and loss of cognitive function in Alzheimers patients.
Neurimmunes unique Reverse Translational Medicine (RTM) technology platform combined with in-depth expertise in neuroscience played a critical role in moving the program forward. The fact that we could reach all preclinical milestones in such a short period of time shows that our RTM technology can significantly accelerate the transition from discovery to development of human monoclonal antibodies, said Jan Grimm, Chief Scientific Officer of Neurimmune Therapeutics.
The rapid advancement into preclinical development demonstrates the progress and productivity of our collaboration with Biogen Idec we are very happy to work with a partner that has such extensive and valuable experience in the development of biopharmaceuticals. The significant milestone payments also provide Neurimmune with additional financial stability to support the sustainable future development of our company, said Michael Salzmann, COO and General Manager of Neurimmune Therapeutics.
Biogen Idec is globally recognized as a leader in the development of innovative therapies for neurologic diseases, and this program is an important entry into Alzheimers disease for us, said Kenneth Rhodes, PhD, Vice President, Discovery Neurobiology, Biogen Idec. The rapid progression of this antibody is the result of a very effective joint collaboration, which capitalized on Neurimmunes novel RTM approach and our proven expertise in neuroscience and the development of therapeutic antibodies.
Alzheimers disease is the most prevalent age-related neurodegenerative disease affecting more than 15 million patients worldwide. There are currently no treatments approved to slow or stop the progression of the disease. Patients with Alzheimers disease experience the progressive loss of cognitive functions, particularly those related to memory, followed by death eight to 15 years after a progressive decline in their disease. The pathology of Alzheimers disease is characterized by distinctive features, including the deposition of Abeta in the form of senile plaques and the loss of specific neuronal populations in the brain.
For further information please contact:
About Neurimmune Therapeutics AG - www.neurimmune.com
Neurimmune Therapeutics AG is a Swiss biotechnology company dedicated to the identification of novel therapeutics for the treatment of human diseases with a focus on neurodegenerative disorders such as Alzheimers disease. Based on novel scientific concepts developed at the University of Zurich, Neurimmune Therapeutics has established a unique technology platform RTM (Reverse Translational Medicine) that supports Neurimmune Therapeutics translational research-focused drug discovery programs.
Neurimmune Therapeutics business strategy focuses on the discovery and development of human-derived antibodies through RTM at an early stage of the pharmaceutical value chain and partnering product candidates targeting significant markets and unmet medical needs with leading biopharmaceutical companies for later-stage development and marketing.
Michael Salzmann, PhD
COO & General Manager
Neurimmune Therapeutics AG
Wagistrasse 13, CH-8952 Schlieren
phone +41 44 755 4646
fax +41 44 755 4647
email@example.com Related biology news :1
. Amarna Therapeutics B.V. and TNO announce SVac research and development partnership2
. Continuous glucose monitoring technology -- special issue of Diabetes Technology and Therapeutics3
. NIH announces new program to develop therapeutics for rare and neglected diseases4
. Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB5
. Tufts University professor receives IADR Pharmacology/Therapeutics/Toxicology Award6
. Acorda Therapeutics submits new drug application for Fampridine-SR in multiple sclerosis7
. A novel target for therapeutics against Staph infection8
. Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration9
. Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics10
. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery11
. Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics